Shandong Taibang Biological Products Co., Ltd. was reorganized and established in 2002 on the basis of the Shandong Provincial Biological Products Research Institute, which has a 50-year history. It is a national high-tech enterprise designated by the state and the only one in Shandong Province that focuses on blood products, integrating research, production, and operations. The company's comprehensive indicators, including technological innovation, advanced equipment and facilities, systematic quality assurance, and standardized management, have positioned it as a leader in the industry nationwide. The company has invested 2.5 billion yuan to build the Taibang Biological Science and Technology Park, covering 260 acres. The park has been listed as a national new drug creation and industrialization project by the National Health Commission and the Ministry of Science and Technology, as well as a demonstration project for the transformation of old and new kinetic energy in the province. The Science and Technology Park is committed to digital transformation and aims to fully achieve "automation, digitization, and intelligence" in the production process. It will have the capacity to process 2,250 tons of plasma and supply over 30 types of blood products urgently needed in the market. This will contribute significantly to ensuring clinical emergency and rare disease treatments, as well as alleviating the severe shortage of blood products in China.

Dalu Heqi is committed to the development of respiratory chronic disease medical care and the silver-haired health industry. The entire project is divided into three sections: respiratory medical care, intelligent respiratory disease management, and respiratory drug formulation. The entire industrial park will be planned and built with a GMP pharmaceutical clean workshop of 100,000 square meters, of which 10,000 square meters of GMP pharmaceutical clean workshop will be built in 2025. The total project investment is 200 million yuan. The economic and social benefits are that the project can realize sales revenue of 300 million yuan per year after production, realize tax revenue of 100 million yuan, and solve employment for 300 people. At present, the medical section belongs to a national high-tech enterprise, a provincial enterprise technology center enterprise, and a provincial specialized and innovative enterprise. The enterprise has more than 100 independent intellectual property rights, and now medical products are exported to 85 countries and regions (Europe, Southeast Asia, the Middle East, Africa, Latin America), with more than 400 agents overseas, and has formed long-term strategic partners in the field of health care.

The company has established strategic CDMO partnerships with world-class pharmaceutical giants such as Johnson & Johnson, Kenvue, and Bayer. Committed to innovation-driven development, Jewim Pharma concentrates its R&D efforts on cutting-edge technologies including:

• Advanced pulmonary inhalation drug delivery systems

• Long-acting microsphere formulations

• Nanoparticle-based drug delivery platforms

Recognized for its scientific research capabilities, Jewim Pharma was ranked 58th among China's top pharmaceutical enterprises in the 2024 National Pharmaceutical R&D Competitiveness Rankings. Our continuous pursuit of technological excellence positions us as a pivotal player in global pharmaceutical innovation.

Jinhao Pharmaceutical (Shandong) Co., Ltd. is a modern pharmaceutical company dedicated to inheriting and promoting the culture of traditional Chinese medicine, innovating and integrating the development of traditional medicine, and taking the responsibility of safeguarding human health.

Jinhao Pharmaceutical Company has been deeply involved in the field of Traditional Chinese Medicine (TCM), focusing on the classic and famous prescriptions. It has the national second-class new medicine of TCM, the national exclusive variety of TCM, and has completed four phase clinical trials of a liver-protective lipid-lowering drug: Suziyou Soft Capsule (Sinopharm 220070052). The inheritance and innovation of traditional Chinese medicine is the responsibility of traditional medicine enterprises. Centering on Jinhao Traditional Chinese Medicine culture and genuine regional drug, the company is constantly expanding the agricultural planting layout based on the pharmaceutical industry. The establishment of a standardized perilla cultivation base in Guyuan, Ningxia Hui Autonomous Region, has created a "company + base + farmers" Chinese herbal medicine cultivation management model, from the source to ensure the quality and safety of Chinese herbal medicine, Traditional Chinese Medicine Patent Prescription standardization and traceability system has contributed.